Prof. Scherbaum had studied medicine in Hamburg and Tuebingen and was promoted to PhD in 1975.
From 1984-1992 Prof. Scherbaum was a senior physician at the Medical Clinic and Polyclinic of the Ulm University Hospital, where he headed the rheumatology department and the immunological laboratory.
In 1993 he accepted a professorship for internal medicine, endocrinology, diabetology, and nephrology at the University of Leipzig.
In 1996 he was offered a position at Heinrich Heine University in Dusseldorf. Until his retirement in summer 2012, he was director of the Clinic for Endocrinology, Diabetology and Rheumatology in Dusseldorf.
National and international awards
In 1997 Prof. Scherbaum and his team received the qualification and the tasks of a "WHO Collaborating Center for Diabetes", which he headed until 2007. From 1997-1998 he was president of the German Diabetes Society (DDG), and from 1997-2009 chairman of the guideline commission of the DDG, in which the standards for diabetes treatment are developed and updated.
From 1996-2012 he was chairman of the scientific advisory board of the Thyroid League Germany. Prof. Scherbaum was President of MEDICA from 2005-2012, where he was also responsible for the medical program at the world's largest medical trade fair, which is located in Düsseldorf. Prof. Scherbaum has received numerous prizes and awards, including the Frerichs Prize (highest research prize) from the German Society for Internal Medicine in 1986 and the Berthold Prize from the German Society for Endocrinology in 2009.
In 2003, Prof. Scherbaum was accepted into the Leopoldina, German Academy of Natural Scientists - National Academy of Sciences.
Prof. Scherbaum is a member of numerous national and international specialist societies, including the Endocrine Society (USA), the European Society of Endocrinology (ESE), the European Diabetes Society (EASD), the German Society for Internal Medicine (DGIM); and the German Diabetes Society (DDG).
Human medicineUniversities of Tübingen and Hamburg
PhD thesis defenseInstitute of Hygiene, Tübingen University
License to practice medicine
Doctoral thesisThe University of Tübingen
Research assistantMedical Polyclinic & Cardiology Department, Tübingen University Hospital
Certificate in Internal Medicine
Research fellowship (German Research Association)Immunology Department, Middlesex-Hospital London, United Kingdom
Sub-specialization in endocrinology
Research assistantMedical Polyclinic, Tübingen University Hospital
Senior physicianInternal Medicine Clinic and Polyclinic, Ulm University Hospital
Sub-specialization in rheumatology
Professor by special appointmentUlm University
Professor of internal medicine with focus on endocrinology and metabolismThe University of Leipzig
DirectorMedical Clinic and Polyclinic III, Leipzig University Hospital
Initiator and spokespersonUniversity of Leipzig Interdisciplinary Centre for Clinical Research (IZKF)
Leipzig University Faculty of Medicine Management Board spokesperson and research officer
Co-founder of Leipzig University Neuro Science Post-Graduate Program
DirectorEndocrinology Clinical Department and German Diabetes Clinic, Heinrich Heine University, Düsseldorf
Professor of Internal Medicine, specializing in endocrinology and metabolismHeinrich Heine University, Düsseldorf
Diabetes mellitus is one of the most common conditions. There are several forms of the disease, differing in cause and course, although in the background is always a disorder of glucose metabolism in the body. Correct and timely diagnosis plays a crucial role in finding the right treatment and monitoring scheme. This means that it is possible to maintain the quality of life for as long as possible, avoiding or minimizing complications. However, it is at the time of diagnosis that mistakes occur quite often.
New generation antidiabetic drugs, which appeared on the market relatively recently, are rightfully considered a breakthrough in the treatment of this widespread and dangerous disease. At the same time, they are not only able to regulate blood sugar levels, but also to fight the frequent "companion" of diabetes - obesity.
Tirzepatide (branded Munjaro) improves blood sugar metabolism in patients with obesity and type 2 diabetes. It is able to reduce body weight by up to 26.6% on average. This was evidenced by the results of SURMOUNT-3 and SURMOUNT- 4, two Phase 3 drug trials. Until now, the its effect on metabolism was not fully understood. Recently scientists have managed to uncover this mechanism.